Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detachment. This study will compare intravitreal injection of anti-vascular endothelial growth factor (ranibizumab) versus sham injection before vitrectomy for PDR. The main focus is to see if pre-operative injection of ranibizuman can reduce peri-operative hemorrahge related complications.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• type I or type II diabetes

• there is clear indications for vitrectomy due to proliferative membrane in the vitreoretinal interface, mild hemorrhage, or tractional retinal detachment

• retinal large vessels could be detected within one PD away from the edge of optic disc by OCT

• microcurculation could be detected by FFA in at least one quadrant

• the patient could tolerant FFA examination

Exclusion Criteria:

• a history of vitrectomy or scleral bucke in the included eye

• retinal laser photocoagulation treatment within 90 days in the included eye

• anti-VEGF treatment with 90 days in either eye

• there is cocurrent neovascular glaucoma in the included eye

• any reason that might hinde the procedure of vitrectomy, FFA OCT or the observation of ocular fudus

• a history of cere-brovascular accident or heart stroke

• renal failure

• could not attend follow up regularly